Pharma & Healthcare

Global Humanized Monoclonal Antibody Drugs Market Research Report 2025

The global market for Humanized Monoclonal Antibody Drugs was valued at US$ 132574 million in the year 2024 and is projected to reach a revised size of US$ 259527 million by 2031, growing at a CAGR of 10.4% during the forecast period.
Humanized monoclonal antibody drugs are therapeutic antibodies that are predominantly derived from human antibody structures, but with small portions—typically the complementarity-determining regions (CDRs)—originating from non-human species, such as mice. These drugs are engineered through recombinant DNA technology to reduce immunogenicity while maintaining high specificity and binding affinity to the target antigen. Humanized antibodies are widely used to treat cancers, autoimmune diseases, and inflammatory conditions.
North American market for Humanized Monoclonal Antibody Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Humanized Monoclonal Antibody Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Humanized Monoclonal Antibody Drugs in Cancers is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Humanized Monoclonal Antibody Drugs include Merck & Co, AbbVie, Eli Lilly & Co, Roche, Takeda, GlaxoSmithKline, UCB, AstraZeneca, Biogen, Gilead Sciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Humanized Monoclonal Antibody Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Humanized Monoclonal Antibody Drugs.
The Humanized Monoclonal Antibody Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Humanized Monoclonal Antibody Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Humanized Monoclonal Antibody Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck & Co
AbbVie
Eli Lilly & Co
Roche
Takeda
GlaxoSmithKline
UCB
AstraZeneca
Biogen
Gilead Sciences
Novartis
Teva
Qilu Pharma
Sun Pharmaceutical
Johnson & Johnson
Beigene
Pfizer
Innovent Bio
Segment by Type
Pembrolizumab
Risenqizumab
Orelizumab
Ixekizumab
Vedolizumab
Bevacizumab
Omalizumab
Farisimab
Trastuzumab
Other
Segment by Application
Cancers
Autoimmune Diseases
Inflammatory Condition
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Humanized Monoclonal Antibody Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Pembrolizumab
1.2.3 Risenqizumab
1.2.4 Orelizumab
1.2.5 Ixekizumab
1.2.6 Vedolizumab
1.2.7 Bevacizumab
1.2.8 Omalizumab
1.2.9 Farisimab
1.2.10 Trastuzumab
1.3 Market by Application
1.3.1 Global Humanized Monoclonal Antibody Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancers
1.3.3 Autoimmune Diseases
1.3.4 Inflammatory Condition
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Humanized Monoclonal Antibody Drugs Market Perspective (2020-2031)
2.2 Global Humanized Monoclonal Antibody Drugs Growth Trends by Region
2.2.1 Global Humanized Monoclonal Antibody Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Humanized Monoclonal Antibody Drugs Historic Market Size by Region (2020-2025)
2.2.3 Humanized Monoclonal Antibody Drugs Forecasted Market Size by Region (2026-2031)
2.3 Humanized Monoclonal Antibody Drugs Market Dynamics
2.3.1 Humanized Monoclonal Antibody Drugs Industry Trends
2.3.2 Humanized Monoclonal Antibody Drugs Market Drivers
2.3.3 Humanized Monoclonal Antibody Drugs Market Challenges
2.3.4 Humanized Monoclonal Antibody Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Humanized Monoclonal Antibody Drugs Players by Revenue
3.1.1 Global Top Humanized Monoclonal Antibody Drugs Players by Revenue (2020-2025)
3.1.2 Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Top Humanized Monoclonal Antibody Drugs Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Humanized Monoclonal Antibody Drugs Revenue
3.4 Global Humanized Monoclonal Antibody Drugs Market Concentration Ratio
3.4.1 Global Humanized Monoclonal Antibody Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Humanized Monoclonal Antibody Drugs Revenue in 2024
3.5 Global Key Players of Humanized Monoclonal Antibody Drugs Head office and Area Served
3.6 Global Key Players of Humanized Monoclonal Antibody Drugs, Product and Application
3.7 Global Key Players of Humanized Monoclonal Antibody Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Humanized Monoclonal Antibody Drugs Breakdown Data by Type
4.1 Global Humanized Monoclonal Antibody Drugs Historic Market Size by Type (2020-2025)
4.2 Global Humanized Monoclonal Antibody Drugs Forecasted Market Size by Type (2026-2031)
5 Humanized Monoclonal Antibody Drugs Breakdown Data by Application
5.1 Global Humanized Monoclonal Antibody Drugs Historic Market Size by Application (2020-2025)
5.2 Global Humanized Monoclonal Antibody Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Humanized Monoclonal Antibody Drugs Market Size (2020-2031)
6.2 North America Humanized Monoclonal Antibody Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Humanized Monoclonal Antibody Drugs Market Size by Country (2020-2025)
6.4 North America Humanized Monoclonal Antibody Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Humanized Monoclonal Antibody Drugs Market Size (2020-2031)
7.2 Europe Humanized Monoclonal Antibody Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2020-2025)
7.4 Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size (2020-2031)
8.2 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Humanized Monoclonal Antibody Drugs Market Size (2020-2031)
9.2 Latin America Humanized Monoclonal Antibody Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Humanized Monoclonal Antibody Drugs Market Size by Country (2020-2025)
9.4 Latin America Humanized Monoclonal Antibody Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size (2020-2031)
10.2 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck & Co
11.1.1 Merck & Co Company Details
11.1.2 Merck & Co Business Overview
11.1.3 Merck & Co Humanized Monoclonal Antibody Drugs Introduction
11.1.4 Merck & Co Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.1.5 Merck & Co Recent Development
11.2 AbbVie
11.2.1 AbbVie Company Details
11.2.2 AbbVie Business Overview
11.2.3 AbbVie Humanized Monoclonal Antibody Drugs Introduction
11.2.4 AbbVie Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.2.5 AbbVie Recent Development
11.3 Eli Lilly & Co
11.3.1 Eli Lilly & Co Company Details
11.3.2 Eli Lilly & Co Business Overview
11.3.3 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Introduction
11.3.4 Eli Lilly & Co Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.3.5 Eli Lilly & Co Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Humanized Monoclonal Antibody Drugs Introduction
11.4.4 Roche Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.4.5 Roche Recent Development
11.5 Takeda
11.5.1 Takeda Company Details
11.5.2 Takeda Business Overview
11.5.3 Takeda Humanized Monoclonal Antibody Drugs Introduction
11.5.4 Takeda Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.5.5 Takeda Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Introduction
11.6.4 GlaxoSmithKline Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.6.5 GlaxoSmithKline Recent Development
11.7 UCB
11.7.1 UCB Company Details
11.7.2 UCB Business Overview
11.7.3 UCB Humanized Monoclonal Antibody Drugs Introduction
11.7.4 UCB Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.7.5 UCB Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Humanized Monoclonal Antibody Drugs Introduction
11.8.4 AstraZeneca Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.8.5 AstraZeneca Recent Development
11.9 Biogen
11.9.1 Biogen Company Details
11.9.2 Biogen Business Overview
11.9.3 Biogen Humanized Monoclonal Antibody Drugs Introduction
11.9.4 Biogen Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.9.5 Biogen Recent Development
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Details
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Humanized Monoclonal Antibody Drugs Introduction
11.10.4 Gilead Sciences Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.10.5 Gilead Sciences Recent Development
11.11 Novartis
11.11.1 Novartis Company Details
11.11.2 Novartis Business Overview
11.11.3 Novartis Humanized Monoclonal Antibody Drugs Introduction
11.11.4 Novartis Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.11.5 Novartis Recent Development
11.12 Teva
11.12.1 Teva Company Details
11.12.2 Teva Business Overview
11.12.3 Teva Humanized Monoclonal Antibody Drugs Introduction
11.12.4 Teva Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.12.5 Teva Recent Development
11.13 Qilu Pharma
11.13.1 Qilu Pharma Company Details
11.13.2 Qilu Pharma Business Overview
11.13.3 Qilu Pharma Humanized Monoclonal Antibody Drugs Introduction
11.13.4 Qilu Pharma Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.13.5 Qilu Pharma Recent Development
11.14 Sun Pharmaceutical
11.14.1 Sun Pharmaceutical Company Details
11.14.2 Sun Pharmaceutical Business Overview
11.14.3 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Introduction
11.14.4 Sun Pharmaceutical Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.14.5 Sun Pharmaceutical Recent Development
11.15 Johnson & Johnson
11.15.1 Johnson & Johnson Company Details
11.15.2 Johnson & Johnson Business Overview
11.15.3 Johnson & Johnson Humanized Monoclonal Antibody Drugs Introduction
11.15.4 Johnson & Johnson Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.15.5 Johnson & Johnson Recent Development
11.16 Beigene
11.16.1 Beigene Company Details
11.16.2 Beigene Business Overview
11.16.3 Beigene Humanized Monoclonal Antibody Drugs Introduction
11.16.4 Beigene Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.16.5 Beigene Recent Development
11.17 Pfizer
11.17.1 Pfizer Company Details
11.17.2 Pfizer Business Overview
11.17.3 Pfizer Humanized Monoclonal Antibody Drugs Introduction
11.17.4 Pfizer Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.17.5 Pfizer Recent Development
11.18 Innovent Bio
11.18.1 Innovent Bio Company Details
11.18.2 Innovent Bio Business Overview
11.18.3 Innovent Bio Humanized Monoclonal Antibody Drugs Introduction
11.18.4 Innovent Bio Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025)
11.18.5 Innovent Bio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Pembrolizumab
Table 3. Key Players of Risenqizumab
Table 4. Key Players of Orelizumab
Table 5. Key Players of Ixekizumab
Table 6. Key Players of Vedolizumab
Table 7. Key Players of Bevacizumab
Table 8. Key Players of Omalizumab
Table 9. Global Humanized Monoclonal Antibody Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Humanized Monoclonal Antibody Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Humanized Monoclonal Antibody Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Humanized Monoclonal Antibody Drugs Market Share by Region (2020-2025)
Table 13. Global Humanized Monoclonal Antibody Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Humanized Monoclonal Antibody Drugs Market Share by Region (2026-2031)
Table 15. Humanized Monoclonal Antibody Drugs Market Trends
Table 16. Humanized Monoclonal Antibody Drugs Market Drivers
Table 17. Humanized Monoclonal Antibody Drugs Market Challenges
Table 18. Humanized Monoclonal Antibody Drugs Market Restraints
Table 19. Global Humanized Monoclonal Antibody Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Humanized Monoclonal Antibody Drugs Market Share by Players (2020-2025)
Table 21. Global Top Humanized Monoclonal Antibody Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Humanized Monoclonal Antibody Drugs as of 2024)
Table 22. Ranking of Global Top Humanized Monoclonal Antibody Drugs Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Humanized Monoclonal Antibody Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Humanized Monoclonal Antibody Drugs, Headquarters and Area Served
Table 25. Global Key Players of Humanized Monoclonal Antibody Drugs, Product and Application
Table 26. Global Key Players of Humanized Monoclonal Antibody Drugs, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Humanized Monoclonal Antibody Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Type (2020-2025)
Table 30. Global Humanized Monoclonal Antibody Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Type (2026-2031)
Table 32. Global Humanized Monoclonal Antibody Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Application (2020-2025)
Table 34. Global Humanized Monoclonal Antibody Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Application (2026-2031)
Table 36. North America Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Humanized Monoclonal Antibody Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Humanized Monoclonal Antibody Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Humanized Monoclonal Antibody Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Humanized Monoclonal Antibody Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 51. Merck & Co Company Details
Table 52. Merck & Co Business Overview
Table 53. Merck & Co Humanized Monoclonal Antibody Drugs Product
Table 54. Merck & Co Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 55. Merck & Co Recent Development
Table 56. AbbVie Company Details
Table 57. AbbVie Business Overview
Table 58. AbbVie Humanized Monoclonal Antibody Drugs Product
Table 59. AbbVie Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 60. AbbVie Recent Development
Table 61. Eli Lilly & Co Company Details
Table 62. Eli Lilly & Co Business Overview
Table 63. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product
Table 64. Eli Lilly & Co Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 65. Eli Lilly & Co Recent Development
Table 66. Roche Company Details
Table 67. Roche Business Overview
Table 68. Roche Humanized Monoclonal Antibody Drugs Product
Table 69. Roche Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 70. Roche Recent Development
Table 71. Takeda Company Details
Table 72. Takeda Business Overview
Table 73. Takeda Humanized Monoclonal Antibody Drugs Product
Table 74. Takeda Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 75. Takeda Recent Development
Table 76. GlaxoSmithKline Company Details
Table 77. GlaxoSmithKline Business Overview
Table 78. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product
Table 79. GlaxoSmithKline Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 80. GlaxoSmithKline Recent Development
Table 81. UCB Company Details
Table 82. UCB Business Overview
Table 83. UCB Humanized Monoclonal Antibody Drugs Product
Table 84. UCB Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 85. UCB Recent Development
Table 86. AstraZeneca Company Details
Table 87. AstraZeneca Business Overview
Table 88. AstraZeneca Humanized Monoclonal Antibody Drugs Product
Table 89. AstraZeneca Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 90. AstraZeneca Recent Development
Table 91. Biogen Company Details
Table 92. Biogen Business Overview
Table 93. Biogen Humanized Monoclonal Antibody Drugs Product
Table 94. Biogen Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 95. Biogen Recent Development
Table 96. Gilead Sciences Company Details
Table 97. Gilead Sciences Business Overview
Table 98. Gilead Sciences Humanized Monoclonal Antibody Drugs Product
Table 99. Gilead Sciences Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 100. Gilead Sciences Recent Development
Table 101. Novartis Company Details
Table 102. Novartis Business Overview
Table 103. Novartis Humanized Monoclonal Antibody Drugs Product
Table 104. Novartis Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 105. Novartis Recent Development
Table 106. Teva Company Details
Table 107. Teva Business Overview
Table 108. Teva Humanized Monoclonal Antibody Drugs Product
Table 109. Teva Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 110. Teva Recent Development
Table 111. Qilu Pharma Company Details
Table 112. Qilu Pharma Business Overview
Table 113. Qilu Pharma Humanized Monoclonal Antibody Drugs Product
Table 114. Qilu Pharma Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 115. Qilu Pharma Recent Development
Table 116. Sun Pharmaceutical Company Details
Table 117. Sun Pharmaceutical Business Overview
Table 118. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product
Table 119. Sun Pharmaceutical Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 120. Sun Pharmaceutical Recent Development
Table 121. Johnson & Johnson Company Details
Table 122. Johnson & Johnson Business Overview
Table 123. Johnson & Johnson Humanized Monoclonal Antibody Drugs Product
Table 124. Johnson & Johnson Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 125. Johnson & Johnson Recent Development
Table 126. Beigene Company Details
Table 127. Beigene Business Overview
Table 128. Beigene Humanized Monoclonal Antibody Drugs Product
Table 129. Beigene Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 130. Beigene Recent Development
Table 131. Pfizer Company Details
Table 132. Pfizer Business Overview
Table 133. Pfizer Humanized Monoclonal Antibody Drugs Product
Table 134. Pfizer Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 135. Pfizer Recent Development
Table 136. Innovent Bio Company Details
Table 137. Innovent Bio Business Overview
Table 138. Innovent Bio Humanized Monoclonal Antibody Drugs Product
Table 139. Innovent Bio Revenue in Humanized Monoclonal Antibody Drugs Business (2020-2025) & (US$ Million)
Table 140. Innovent Bio Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
Table 144. Authors List of This Report


List of Figures
Figure 1. Humanized Monoclonal Antibody Drugs Picture
Figure 2. Global Humanized Monoclonal Antibody Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Humanized Monoclonal Antibody Drugs Market Share by Type: 2024 VS 2031
Figure 4. Pembrolizumab Features
Figure 5. Risenqizumab Features
Figure 6. Orelizumab Features
Figure 7. Ixekizumab Features
Figure 8. Vedolizumab Features
Figure 9. Bevacizumab Features
Figure 10. Omalizumab Features
Figure 11. Farisimab Features
Figure 12. Trastuzumab Features
Figure 13. Global Humanized Monoclonal Antibody Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 14. Global Humanized Monoclonal Antibody Drugs Market Share by Application: 2024 VS 2031
Figure 15. Cancers Case Studies
Figure 16. Autoimmune Diseases Case Studies
Figure 17. Inflammatory Condition Case Studies
Figure 18. Humanized Monoclonal Antibody Drugs Report Years Considered
Figure 19. Global Humanized Monoclonal Antibody Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 20. Global Humanized Monoclonal Antibody Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 21. Global Humanized Monoclonal Antibody Drugs Market Share by Region: 2024 VS 2031
Figure 22. Global Humanized Monoclonal Antibody Drugs Market Share by Players in 2024
Figure 23. Global Humanized Monoclonal Antibody Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 24. The Top 10 and 5 Players Market Share by Humanized Monoclonal Antibody Drugs Revenue in 2024
Figure 25. North America Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. North America Humanized Monoclonal Antibody Drugs Market Share by Country (2020-2031)
Figure 27. United States Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Canada Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Europe Humanized Monoclonal Antibody Drugs Market Share by Country (2020-2031)
Figure 31. Germany Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. France Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. U.K. Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Italy Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Russia Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Ireland Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Share by Region (2020-2031)
Figure 39. China Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Japan Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. South Korea Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. India Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Australia & New Zealand Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Latin America Humanized Monoclonal Antibody Drugs Market Share by Country (2020-2031)
Figure 47. Mexico Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Brazil Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share by Country (2020-2031)
Figure 51. Israel Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. UAE Humanized Monoclonal Antibody Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Merck & Co Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 55. AbbVie Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 56. Eli Lilly & Co Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 57. Roche Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 58. Takeda Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 59. GlaxoSmithKline Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 60. UCB Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 61. AstraZeneca Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 62. Biogen Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 63. Gilead Sciences Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 64. Novartis Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 65. Teva Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 66. Qilu Pharma Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 67. Sun Pharmaceutical Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 68. Johnson & Johnson Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 69. Beigene Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 70. Pfizer Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 71. Innovent Bio Revenue Growth Rate in Humanized Monoclonal Antibody Drugs Business (2020-2025)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies